Suppr超能文献

以壳聚糖为基础的 Eudragit® L100 包衣纳米粒的合成及其口服依诺肝素给药系统。

Synthesis of Eudragit® L100-coated chitosan-based nanoparticles for oral enoxaparin delivery.

机构信息

Quality Control Core of Medicines and Correlates, Federal University of Pernambuco, Recife, PE, Brazil.

Quality Control Core of Medicines and Correlates, Federal University of Pernambuco, Recife, PE, Brazil; Department of Immunology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), Brazil.

出版信息

Int J Biol Macromol. 2021 Dec 15;193(Pt A):450-456. doi: 10.1016/j.ijbiomac.2021.10.111. Epub 2021 Oct 21.

Abstract

Enoxaparin is an effective biological molecule for prevention and treatment of coagulation disorders. However, it is poorly absorbed in the gastrointestinal tract. In this study, we developed an Eudragit® L100 coated chitosan core shell nanoparticles for enoxaparin oral delivery (Eud/CS/Enox NPs) through a completely eco-friendly method without employing any high-energy homogenizer technique and any organic solvents. Spherical nanocarriers were successfully prepared with particle size lower than 300 nm, polydispersity index about 0.12 and zeta potential higher than +25 mV, entrapment efficiency greater than 95% and the in vitro release behavior confirms the good colloidal stability and the successful Eudragit® L100 coating process demonstrated by negligible cumulative enoxaparin release (<10%) when the particles are submitted to simulated gastric fluid conditions. Finally, we demonstrated that the core-shell structure of the particle influenced the drug release mechanism of the formulations, indicating the presence of the Eudragit® L100 on the surface of the particles. These results suggested that enteric-coating approach and drug delivery nanotechnology can be successfully explored as potential tools for oral delivery of enoxaparin.

摘要

依诺肝素是一种有效的生物分子,可用于预防和治疗凝血障碍。然而,它在胃肠道中的吸收较差。在这项研究中,我们通过一种完全环保的方法,不使用任何高能匀浆技术和有机溶剂,开发了一种用于依诺肝素口服给药的 Eudragit®L100 包衣壳聚糖核壳纳米粒(Eud/CS/Enox NPs)。成功制备了粒径小于 300nm、多分散指数约为 0.12、Zeta 电位高于+25mV 的球形纳米载体,包封效率大于 95%,体外释放行为证实了良好的胶体稳定性和 Eudragit®L100 包衣过程的成功,当颗粒处于模拟胃液条件下时,依诺肝素的累积释放量(<10%)可忽略不计。最后,我们证明了颗粒的核壳结构影响了制剂的药物释放机制,表明颗粒表面存在 Eudragit®L100。这些结果表明,肠溶性包衣方法和药物传递纳米技术可以作为依诺肝素口服给药的潜在工具进行探索。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验